dual PI3K/HDAC inhibitors (Dana-Farber Cancer Institute)

N/A

Report date: 2025/01/26 18:33:49
NME

Base Information

Drug Namedual PI3K/HDAC inhibitors (Dana-Farber Cancer Institute)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionHistone deacetylase 6 inhibitorsPI3-kinase class I inhibitors
TargetsHistone deacetylase 6PI3-kinase class I
Therapy Area/IndicationsNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesDana-Farber Cancer Institute
China Registration ClassN/A

Develop Information

Active CompaniesDana-Farber Cancer Institute
Inactive CompaniesN/A
Active IndicationsNeoplasms
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A